Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPT101 in Recent Onset Type 1 Diabetes Mellitus
NCT06964087Phase 2Recruiting
- Sponsor
- Op-T
- Start
- Apr 2026
- Primary completion
- May 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of OPT101 in type 1 diabetes mellitus (T1D), sponsored by Op-T. Started Apr 2026; status: recruiting.
02
Drugs
OPT101
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06964087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06964087.